Cargando…
Beyond FDG: novel PET tracers for cancer imaging
Despite the excellent clinical performance of fluorodeoxyglucose (FDG) as a cancer-imaging agent for positron emission tomography (PET), false positive and false negative results can be problematic in some clinical settings. Radiopharmaceutical development has recently focussed on the search for new...
| Autor principal: | |
|---|---|
| Formato: | Texto |
| Lenguaje: | English |
| Publicado: |
e-MED
2003
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1434524/ https://www.ncbi.nlm.nih.gov/pubmed/18211857 http://dx.doi.org/10.1102/1470-7330.2003.0032 |